NASDAQ · ITRM
Healthcare · Biotechnology
$0.03
Down-$0.00 (-10.98%)
Updated Sep 1, 2026, 9:56 PM
SID Score
2.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
ITRM does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning ITRM.
ITRM research
Company profile and research snapshot.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 30, 2026 | HC Wainwright & Co. | Neutral | — |
| Sep 10, 2024 | HC Wainwright & Co. | Buy | — |
| Aug 15, 2024 | HC Wainwright & Co. | Buy | — |
| Jun 21, 2024 | HC Wainwright & Co. | Buy | — |
| May 31, 2024 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Mar 3, 2026
U.S. stocks traded lower this morning, with the Dow Jones index falling more than 900 points on Tuesday amid the ongoing Iran-U.S. conflict. Iranian state media reported that Tehran has closed the Strait of Hormuz and warned it would fire on any vessel attempting to pass.
Benzinga · Feb 13, 2026
ITRM reaches another signed rebate agreement with one of the top three Medicare Part D Pharmacy Benefit Managers;Iterum has been granted a patent in the United States that covers a bilayer tablet comprising
Yahoo · Nov 14, 2025
Iterum Therapeutics PLC (ITRM) reports successful Orlinva launch amidst rising expenses and capital needs.
Yahoo · Nov 14, 2025
--Commercially Launched ORLYNVAH™ in the United States in August 2025-- --Extended Cash Runway into Q2 2026-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company or Iterum), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results fo
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ITRM.
